Literature DB >> 2251873

Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines.

J D Clemens1, D A Sack, J Chakraborty, M R Rao, F Ahmed, J R Harris, F van Loon, M R Khan, M Yunis, S Huda.   

Abstract

In a field trial conducted in Bangladesh, ingestion of either B subunit-killed whole cell (BS-WC) or killed whole cell (WC) oral cholera vaccines by mothers was associated with a 47% reduction of the risk of cholera in their non-vaccinated children aged under 36 months. Because vaccine-induced breast-milk immunity seemed a possible explanation for these findings, we evaluated anti-lipopolysaccharide (LPS) and anti-cholera toxin (CT) IgA antibody responses in breast milk collected during the trial from 53 lactating women who ingested three doses of BS-WC, WC, or an Escherichia coli K12 strain (K12). Despite induction of moderate vibriocidal (1.4 to 2.0-fold) and anti-CT (4.5-fold) serum antibody responses, the vaccines did not elicit significant rises of anti-LPS or anti-CT IgA breast-milk antibodies. The failure of the vaccines to elicit significant levels of breast-milk anti-cholera antibodies suggests an alternative explanation for protection of young children by maternal vaccination, such as interruption of maternal-child transmission of Vibrio cholerae 01.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251873     DOI: 10.1016/0264-410x(90)90248-k

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

2.  Factors Associated with Fatal Outcomes Following Cholera-Like Syndrome in Far North Region of Cameroon: A Community-Based Survey.

Authors:  Fabrice N Djouma; Jerome Ateudjieu; Malathi Ram; Amanda K Debes; David A Sack
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

Review 3.  Killed oral cholera vaccines: history, development and implementation challenges.

Authors:  Anna Lena Lopez; Maria Liza Antoinette Gonzales; Josephine G Aldaba; G Balakrish Nair
Journal:  Ther Adv Vaccines       Date:  2014-09

Review 4.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

Review 5.  Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.

Authors:  Firdausi Qadri; Ann-Mari Svennerholm; A S G Faruque; R Bradley Sack
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  Spatial and environmental connectivity analysis in a cholera vaccine trial.

Authors:  Michael Emch; Mohammad Ali; Elisabeth D Root; Mohammad Yunus
Journal:  Soc Sci Med       Date:  2009-01-08       Impact factor: 4.634

7.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

8.  Cholera in ecuador: current relevance of past lessons learnt.

Authors:  Ss Malavade; A Narvaez; A Mitra; T Ochoa; E Naik; M Sharma; S Galwankar; Md Breglia; R Izurieta
Journal:  J Glob Infect Dis       Date:  2011-04

9.  Review of oral cholera vaccines: efficacy in young children.

Authors:  Cristina Masuet Aumatell; J M Ramon Torrell; Jane N Zuckerman
Journal:  Infect Drug Resist       Date:  2011-09-14       Impact factor: 4.003

10.  A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.

Authors:  Deborah R Leitner; Sabine Lichtenegger; Philipp Temel; Franz G Zingl; Desiree Ratzberger; Sandro Roier; Kristina Schild-Prüfert; Sandra Feichter; Joachim Reidl; Stefan Schild
Journal:  Front Microbiol       Date:  2015-08-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.